Abstract

Between Necessity and Compliance: Understanding FDA’s GFI #256 for Animal Drug Compounding

Author(s): Vogel Jordan T, Howard Brad

Issue: Jan/Feb 2026 - Volume 30, Number 1

Page(s): 6-11

Download in electronic PDF format for $75
  • Between Necessity and Compliance: Understanding FDA’s GFI #256 for Animal Drug Compounding Page 1
  • Between Necessity and Compliance: Understanding FDA’s GFI #256 for Animal Drug Compounding Page 2
  • Between Necessity and Compliance: Understanding FDA’s GFI #256 for Animal Drug Compounding Page 3
  • Between Necessity and Compliance: Understanding FDA’s GFI #256 for Animal Drug Compounding Page 4
  • Between Necessity and Compliance: Understanding FDA’s GFI #256 for Animal Drug Compounding Page 5
  • Between Necessity and Compliance: Understanding FDA’s GFI #256 for Animal Drug Compounding Page 6

Abstract

The practice of compounding animal drugs using bulk drug substances presents a challenging intersection of veterinary need and federal regulatory compliance. Governed by the Federal Food, Drug, and Cosmetic Act (“FDCA”), this area of animal healthcare has long operated in a legal gray zone, with the FDA traditionally exercising discretion in its enforcement. To bring clarity to this nuanced issue, the FDA issued Guidance for Industry #256 (“GFI #256”), which outlines the specific circumstances under which the agency will decline to take enforcement action against compounders of animal drugs using bulk drug substances. This article explores the practical implications of GFI #256 for veterinarians and compounders, focusing on three critical requirements that must be met when compounding bulk drug substances for non-food-producing animals under a patient-specific prescription. stakeholders can better navigate the complex regulatory landscape and ensure their practices align with FDA expectations.

Related Keywords

  • Animal Drugs
  • Animal Health
  • Bulk Drug Substances
  • Clinical Difference
  • Compounding
  • Copy
  • FDA
  • GFI #256
  • Guidance
  • Guidance for Industry 256
  • Medical Rationale
  • Pharmacy
  • Veterinarian

Related Categories

  • LEGAL
  • VETERINARY

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jan/Feb 2026
Pg. 6-11
Between Necessity and Compliance: Understanding FDA’s GFI #256 for Animal Drug Compounding
Author(s): Vogel Jordan T, Howard Brad
Jul/Aug 2015
Pg. 303-305
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Author(s): Miller David G
May/Jun 2020
Pg. 198-199
U.S. Food and Drug Administration Takes Aim (Again) at Animal Compounding: Draft Guidance for Industry #256 Lacks Authority, Will Increase Costs, and Put Pets at Risk
Author(s): Brunner Scott
Sep/Oct 2014
Pg. 379-380
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A
Author(s): Blankenship Cynthia E
Nov/Dec 2015
Pg. 449-450
International Academy of Compounding Pharmacists' Legislative Regulatory Update: Take Action! Stop the U.S. Good and Drug Administration's Misguided Veterminary Guidance
Author(s): Miller David G
Jul/Aug 2016
Pg. 351
View Sample
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Author(s): Allen Loyd V Jr
Sep/Oct 2017
Pg. 356
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Author(s): Allen Loyd V Jr
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
Mar/Apr 2022
Pg. 100-109
Allowing Compounding Pharmacies to Address Drug Shortages
Author(s): Broughel James
Mar/Apr 2022
Pg. 92
PreScription: Comments on the FDA Guidance "Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry"
Author(s): Allen Loyd V Jr
Jan/Feb 2005
Pg. 44-46
The US FDA List of Drugs Not to Be Used in Compounded Medications for Humans (the "Negative List")
Author(s): Allen Loyd V Jr, Ashworth Lisa D
May/Jun 2016
Pg. 202-206
Does Your Drug Expertise Include Clinical Pharmaceutics?
Author(s): Newton David W
Mar/Apr 2018
Pg. 92
PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing
Author(s): Allen Loyd V Jr
May/Jun 2021
Pg. 206-209
FDA-funded Report on Compounded Hormones is Tainted, Analysis Shows
Author(s): Brunner Scott
Sep/Oct 2021
Pg. 358-362
Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA
Author(s): Cabaleiro Joe
Jan/Feb 2020
Pg. 30-36
Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Author(s): Dillon L R
Jul/Aug 2020
Pg. 296-297
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Author(s): Brunner Scott
Sep/Oct 2015
Pg. 389-390
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Author(s): Allen Loyd V Jr
Sep/Oct 1998
Pg. 347-349
TPN Bulk Compounding from Bulk Drug Substances
Author(s): Chamallas Stanley N
Nov/Dec 2011
Pg. 526-527
PostScription: Drug Disposal: Compounding Pharmacists' Involvement in the Prevention of Prescription Drug Misuse and Abuse
Author(s): Williams LaVonn A